PMID: 11310592Apr 20, 2001Paper

Synthesis and pharmacological evaluation of imidazoline sites I1 and I2 selective ligands

Bioorganic & Medicinal Chemistry
M AnastassiadouP Renard

Abstract

Several series of 2-aryl or heterocyclic-imidazoline compounds have been prepared and evaluated in vitro as imidazoline sites (I1 and I2) and alpha-adrenergic (alpha1 and alpha2) receptor ligands. Their pKi values indicate that linkage of the imidazoline moiety at the 2-position with an aromatic substituent dramatically decreases alpha-adrenergic affinity. I1 sites are more accessible by phenyl imidazolines substituted by a methyl or a methoxy group at the ortho or meta position. Indeed, 2-(2'-methoxyphenyl)-imidazoline (17) is one of the best I1 ligands ever reported (pKi = 8.53 and I1/I2 > 3388). On the other hand, I2 selectivity increases in the presence of a methyl group in the para position. The original compound, 2-(3'-fluoro-4'-tolyl)-imidazoline (31) is a new potent ligand for the I2 sites with high selectivity (pKi = 8.53 and I2/I1 > 3388).

References

Oct 1, 1979·Archiv der Pharmazie·F Gaedcke, F Zymalkowski
Apr 1, 1978·Journal of Medicinal Chemistry·M HarfenistG M McKenzie
Jan 25, 1991·European Journal of Pharmacology·V Lachaud-PettitiA Parini
Sep 30, 1987·Biochemical and Biophysical Research Communications·I CoupryA Parini
Nov 1, 1969·Journal of Medicinal Chemistry·J W McFarlandD H Morgan
Jun 1, 1982·Journal of Medicinal Chemistry·J M CaroonR L Whiting
Jul 12, 1995·Annals of the New York Academy of Sciences·D J NuttL Lione
Jul 12, 1995·Annals of the New York Academy of Sciences·G SteffenP Dominiak
Jul 12, 1995·Annals of the New York Academy of Sciences·M Dubar, G Pillion
Feb 23, 1993·European Journal of Pharmacology·A C MacKinnonC M Brown
Jan 1, 1994·European Journal of Pharmacology·G BriccaP Bousquet
Jul 1, 1993·Naunyn-Schmiedeberg's Archives of Pharmacology·G J MolderingsM Göthert
Feb 1, 1996·Journal of Clinical Pharmacology·A Yu, W H Frishman
May 1, 1997·Bioorganic & Medicinal Chemistry·A CarrieriA Carotti

❮ Previous
Next ❯

Citations

Dec 31, 2003·Bioorganic & Medicinal Chemistry Letters·Richard A GlennonAlan L Hudson
Mar 12, 2004·Bioorganic & Medicinal Chemistry Letters·Jean Chang-FongRichard A Glennon
Mar 12, 2002·Bioorganic & Medicinal Chemistry·Christophe DardonvilleJ Javier Meana
Feb 24, 2012·Pharmacological Reports : PR·Jerusalem TesfaiLincoln P Edwards
Sep 3, 2011·Cardiovascular Therapeutics·K Nikolic, D Agbaba
Mar 4, 2011·Synapse·Kazunori KawamuraMing-Rong Zhang
Aug 13, 2011·Nuclear Medicine and Biology·Kazunori KawamuraMing-Rong Zhang
Sep 13, 2005·European Journal of Medicinal Chemistry·Nathalie DiasJean-Yves Mérour
Jun 30, 2004·Medicinal Research Reviews·Christophe Dardonville, Isabel Rozas
Dec 12, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Steven KealeyAntony D Gee
May 2, 2003·Journal of Medicinal Chemistry·Frédérique TouzeauJean-Yves Mérour
Dec 10, 2008·Bioorganic & Medicinal Chemistry Letters·Gabriela da S Sant' AnnaMarcos A P Martins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.